69 related articles for article (PubMed ID: 17952739)
1. Akt-induced tamoxifen resistance is associated with altered FKHR regulation.
Silva J; Cavazos DA; Donzis E; Friedrichs WE; Marciniak R; deGraffenried LA
Cancer Invest; 2007; 25(7):569-73. PubMed ID: 17952739
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
3. Expression of constitutively active Akt-3 in MCF-7 breast cancer cells reverses the estrogen and tamoxifen responsivity of these cells in vivo.
Faridi J; Wang L; Endemann G; Roth RA
Clin Cancer Res; 2003 Aug; 9(8):2933-9. PubMed ID: 12912939
[TBL] [Abstract][Full Text] [Related]
4. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth.
Frogne T; Jepsen JS; Larsen SS; Fog CK; Brockdorff BL; Lykkesfeldt AE
Endocr Relat Cancer; 2005 Sep; 12(3):599-614. PubMed ID: 16172194
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
6. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer.
Yoo YA; Kim YH; Kim JS; Seo JH
Biochim Biophys Acta; 2008 Mar; 1783(3):438-47. PubMed ID: 18164268
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
8. Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor.
Weng SC; Kashida Y; Kulp SK; Wang D; Brueggemeier RW; Shapiro CL; Chen CS
Mol Cancer Ther; 2008 Apr; 7(4):800-8. PubMed ID: 18413793
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
Sabnis G; Goloubeva O; Jelovac D; Schayowitz A; Brodie A
Clin Cancer Res; 2007 May; 13(9):2751-7. PubMed ID: 17473209
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
11. NF-kappa B inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen.
deGraffenried LA; Chandrasekar B; Friedrichs WE; Donzis E; Silva J; Hidalgo M; Freeman JW; Weiss GR
Ann Oncol; 2004 Jun; 15(6):885-90. PubMed ID: 15151944
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
15. Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen.
Glaros S; Atanaskova N; Zhao C; Skafar DF; Reddy KB
Mol Endocrinol; 2006 May; 20(5):996-1008. PubMed ID: 16455819
[TBL] [Abstract][Full Text] [Related]
16. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US
PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831
[TBL] [Abstract][Full Text] [Related]
17. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition.
Shah KN; Mehta KR; Peterson D; Evangelista M; Livesey JC; Faridi JS
Mol Cancer Res; 2014 Mar; 12(3):394-407. PubMed ID: 24362250
[TBL] [Abstract][Full Text] [Related]
18. Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.
Stoica GE; Franke TF; Moroni M; Mueller S; Morgan E; Iann MC; Winder AD; Reiter R; Wellstein A; Martin MB; Stoica A
Oncogene; 2003 Sep; 22(39):7998-8011. PubMed ID: 12970748
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation and nuclear exclusion of the forkhead transcription factor FKHR after epidermal growth factor treatment in human breast cancer cells.
Jackson JG; Kreisberg JI; Koterba AP; Yee D; Brattain MG
Oncogene; 2000 Sep; 19(40):4574-81. PubMed ID: 11030146
[TBL] [Abstract][Full Text] [Related]
20. Protein pathway activation mapping reveals molecular networks associated with antiestrogen resistance in breast cancer cell lines.
van Agthoven T; Godinho MF; Wulfkuhle JD; Petricoin EF; Dorssers LC
Int J Cancer; 2012 Nov; 131(9):1998-2007. PubMed ID: 22328489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
